Clinical Trial Detail

NCT ID NCT01763164
Title Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis|Novartis Pharmaceuticals
Indications

melanoma

Therapies

Dacarbazine

Binimetinib

Age Groups: adult

Additional content available in CKB BOOST